DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ampyra (Dalfampridine) - Drug Interactions, Contraindications, Overdosage, etc

 
 



DRUG INTERACTIONS

In humans, dalfampridine is eliminated predominantly unchanged by the kidneys. No clinically significant drug interaction was identified. In particular, no interaction was identified between dalfampridine and baclofen [see Clinical Pharmacology, Pharmacokinetics].

OVERDOSAGE

Three cases of overdose were reported in controlled clinical trials with AMPYRA, involving two MS patients. The first patient took six times the currently recommended dose (60 mg) and was taken to the emergency room with altered mental state. The second patient took 40 mg doses on two separate occasions. In the first instance, she experienced a complex partial seizure and, in the second instance, a period of confusion. Both patients recovered by the following day without sequelae.

Several cases of overdose are found in the scientific literature in which various formulations of dalfampridine were used, resulting in numerous adverse events including seizure, confusion, tremulousness, diaphoresis, and amnesia. In some instances, patients developed status epilepticus, requiring intensive supportive care and were responsive to standard therapy for seizures. In one published case report, an MS patient who ingested 300 mg of 4-aminopyridine (dalfampridine) developed a condition that resembled limbic encephalitis. This patient developed weakness, reduced awareness, memory loss, hypophonic speech, and temporal lobe hyperintensities on MRI. The patient's speech and language and ambulation improved over time, and an MRI at 4 months after the overdose no longer showed signal abnormalities. At one year, the patient continued to have difficulty with short term memory and learning new tasks.

CONTRAINDICATIONS

The use of AMPYRA is contraindicated in the following conditions:

  • History of seizure
  • Moderate or severe renal impairment (CrCl≤50 mL/min)
  • History of hypersensitivity to AMPYRA or 4-aminopyridine

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017